EMA PRAC Mandates DHPCs and Label Updates for Desogestrel, Etonogestrel Contraceptives and Litfulo

Marketing authorisation holders for desogestrel- and etonogestrel-containing contraceptives and the JAK inhibitor Litfulo (ritlecitinib) face immediate product information updates and direct healthcare professional communication (DHPC) obligations following the EMA Pharmacovigilance Risk Assessment Committee (PRAC) meeting of 6–9 July 2026. Regulatory affairs and QA teams should treat agreed communication plans as live deliverables.

For desogestrel and etonogestrel, PRAC's recommendations follow a large French epidemiological study identifying a small but statistically supported increased risk of intracranial meningioma associated with current, prolonged use exceeding one year. The absolute risk remains low, one additional meningioma estimated per 67,300 women, but the signal is sufficient to trigger new contraindications, revised warnings, and a class-level DHPC. Product information must now list meningioma as an adverse reaction with frequency "not known," add a contraindication for women with a current or prior meningioma diagnosis, and include monitoring guidance covering visual changes, hearing loss, anosmia, worsening headache, memory loss, seizures, and limb weakness.

Regulatory teams should also note the prior-exposure consideration: women with previous use of progestogens already linked to meningioma risk, including cyproterone, nomegestrol, medroxyprogesterone, and chlormadinone, may carry elevated baseline risk. This history must be factored into prescribing decisions and reflected accurately in updated labelling. Desogestrel is marketed as oral tablets; etonogestrel as subdermal implants and, in combination with ethinylestradiol, as vaginal rings, each presentation requiring its own label revision under applicable EU variation procedures.

The Litfulo update carries a different regulatory mechanism but equivalent urgency. PRAC has agreed to add a boxed warning to the product information, aligning Litfulo's risk profile with the broader JAK inhibitor class signal covering major cardiovascular events, venous thromboembolism, malignancy, and serious infections. The boxed warning restricts use in patients aged 65 or above, those with elevated cardiovascular risk, long-term smokers, and patients at increased cancer risk, unless no suitable treatment alternative exists. Additional caution is required for patients with VTE risk factors beyond those categories.

For QA and regulatory operations, the critical path runs through DHPC dissemination: marketing authorisation holders are responsible for distributing communications to healthcare professionals according to agreed plans, with subsequent publication on EMA's Direct Healthcare Professional Communications page and in national registers across EU member states. Variation submissions to update product information must be sequenced against those communication timelines to avoid label-communication misalignment during inspections.

The measurable checkpoint for both programmes is confirmed DHPC dissemination and national register publication, against which competent authorities will assess MAH compliance with the agreed communication plans.

Source: European Medicines Agency (EMA) via ema.europa.eu, 10 July 2026.